CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...

Despite a challenging macro environment, 10x Genomics Inc (TXG) focuses on product innovation and biopharma expansion to ...

The company launched several new products across its platforms, aiming for future growth. 2025 revenue guidance suggests 0-3% growth, with a focus on biopharma and single-cell projects.

Matthew Larew; Analyst; William Blair & Company L.L.C. Matthew Sykes; Analyst; Goldman Sachs Group, Inc. Thank you for standing by. My name is Stella, and I will be your conference operator today ...

The stock dropped 6.75% in aftermarket trading following the earnings announcement. The company launched several new products across its platforms, aiming for future growth. 2025 revenue guidance ...

Matthew Larew; Analyst; William Blair & Company L.L.C. Matthew Sykes; Analyst; Goldman Sachs Group, Inc. Thank you for standing by. My name is Stella, and I will be your conference operator today. At ...